Evidence map›Paper›PMID 39261070›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension.

Taichi Ozeki, Hisao Higo, Hiroki Omori, Shunta Mori, Shin Tanaka, Go Makimoto, Kiichiro Ninomiya, Akihiko Taniguchi, Masanori Fujii, Kentaro Miyoshi and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Taichi OzekiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Hisao HigoDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Hiroki OmoriDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Shunta MoriDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Shin TanakaOrgan Transplant Center, Okayama University Hospital, Japan.
Go MakimotoDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Japan.
Akihiko TaniguchiDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Japan.
Masanori FujiiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Kentaro MiyoshiDepartment of Thoracic Surgery, Okayama University Hospital, Japan.
Kammei RaiCenter for Innovative Clinical Medicine, Okayama University Hospital, Japan.
Eiki IchiharaCenter for Clinical Oncology, Okayama University Hospital, Japan.
Kadoaki OhashiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Seiichiro SugimotoOrgan Transplant Center, Okayama University Hospital, Japan.
Katsuyuki HottaCenter for Innovative Clinical Medicine, Okayama University Hospital, Japan.
Masahiro TabataCenter for Clinical Oncology, Okayama University Hospital, Japan.
Shinichi ToyookaDepartment of Thoracic Surgery, Okayama University Hospital, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Nobuaki MiyaharaDepartment of Medical Technology, Okayama University Graduate School of Health Sciences, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 55-year-old man presented to our hospital with idiopathic pulmonary fibrosis (IPF). He was registered with the Japan Organ Transplant Network the following year due to disease progression. Treatment with clarithromycin, ethambutol, and rifampicin for complications of Mycobacterium avium pulmonary disease was initiated, but sputum conversion could not be achieved. The administration of an amikacin liposome inhalation suspension (ALIS) resulted in sputum conversion, and single-lung transplantation was performed. ALIS therapy was continued after lung transplantation, and no M. avium disease was observed for 15 months. ALIS may cause M. avium pulmonary disease with additional indications for lung transplantation.

Indexed as

AmikacinAnti-Bacterial AgentsLung TransplantationMycobacterium avium-intracellulare InfectionAdministration, InhalationHumansIdiopathic Pulmonary FibrosisLiposomesMaleMiddle AgedTreatment OutcomeAmikacinAnti-Bacterial AgentsLiposomesamikacin liposome inhalation suspensionidiopathic pulmonary fibrosislung transplantationMycobacterium avium

Identifiers

PMID39261070
PMCPMC12021496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.